Jun 16, 2022 / 06:00PM GMT
Jason Butler - JMP Securities LLC - Analyst
Great. Well, thank you for being with us again this afternoon at the JMP Securities Life Science Conference. Excited to have a discussion with Gamida Cell next. Gamida Cell is focused on novel -- potentially curative therapies for patients with hematological malignancies. Lead program, omidubicel, has shown really positive data in the transplant setting. And then there's a pipeline of NK, natural killer cell-enabled programs coming up behind that.
So excited to be joined by the company's -- I'm sorry -- company's CEO, Julian. Thank you for being here. And Michele Korfin, company's COO and Chief Commercial Officer. So Julian, with that, maybe I just ask you to give a quick intro and overview of Gamida Cell.
Julian Adams - Gamida Cell Ltd. - CEO
Yeah. Well, thank you, Jason, and thank you, JMP, for having us. It's good to be in person again. Not a great day, but it's good to be in person.
Gamida Cell has recently had some really good news vis-Ã -vis FDA interactions. We submitted our BLA for omidubicel
Gamida Cell Ltd at JMP Securities Life Sciences Conference - Fireside Chat Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers